Bicara Therapeutics paid its 3 named executives $2.5M in total in FY2025 (Dec). CEO Claire Mazumdar, Ph.D. was paid $927.7K of that.
Pay$100 in the stock at the end of FY24 → $97
Pay of each named executive
Claire Mazumdar, Ph.D.Chief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
Ryan Cohlhepp, Pharm.D.President and Chief Operating Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) |
2 years
David Raben, M.D.Chief Medical Officer
| FY2025 (Dec) |
1 year
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.